DNER and neoplasm: The lack of significant responses is consistent with other studies of BET inhibitors, none of which have observed significant responses in solid tumours.11,12,24 The results of this study, when contextualised with the results of other Phase 1 studies of BET inhibitors in solid tumours, convey evidence of no strong signal of efficacy as a monotherapy in tumour types other than NMC.